New Strategy for Prostate Cancer Prevention Based on Selenium Suppression of Androgen Receptor Signaling
Abstract
Early stage prostate cancer depends heavily on androgen signaling for growth and clonal expansion. In the previous report, we have demonstrated the combination of selenium, which down-regulates androgen receptor, and finasteride, a 5alpha-reductase inhibitor, has a synerigistic effect in inhibiting the growth of prostate cancer cells, suggesting this novel combination is a promising strategy for preventing prostate cancer. We have also demonstrated that FOXOlA plays a critical role in mediating apoptosis induction by selenium. In the second grant period, we have focused our effort on the following areas: (1) studying the impact of the selenium and finasteride combination on androgen signaling; (2) Identifying the pro-apoptotic target genes of FOXO1 that are induced by selenium; (3) studying the potential AR antagonistic effect of finasteride. The last was not proposed in the original application. But we strongly believe this is a topic worthwhile pursuing since a thorough understanding of the activities of finasteride is important for its use in clinical practices.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2007
- Accession Number
- ADA475532
Entities
People
- Haitao Zhang
Organizations
- Health Research, Incorporated